Mesoridazine

CHEMBL1088 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

386.6 g/mol

LogP

4.5

Phase

4

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

Moleküler Ağırlık

386,6000 g/mol

LogP

4,50

TPSA

68,10 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Schizophrenia Bipolar Disorder Obesity

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21

InChI

InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

Molecular Formula

C21H26N2OS2

HBD / HBA

- / 5

Döndürülebilir Bağlar

4

Ağır Atomlar

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Mesoridazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1088. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4078. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Mesoridazine PillFYI'da

Yapı

Hızlı Veriler

Formül: C21H26N2OS2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.